On February 2, 2025, Shanghai Henlius Biotech, Inc. (“Henlius”) announced FDA acceptance of the Biologics License Application (BLA) for HLX11, a proposed biosimilar to Genentech’s PERJETA.

Shanghai Henlius Biotech, Inc. Class H (HK:2696) has released an update. Shanghai Henlius Biotech, Inc. has achieved a significant milestone with the acceptance of their New Drug Application for ...

The FDA has approved a third biosimilar for tocilizumab, called Avtozma, the second such biosimilar to be available in both intravenous and subcutaneous formulations, according to a press release.

Hence, the rising incidence of breast cancer is a crucial driver of the growth of the herceptin biosimilars market. Who Are The Major Industry Players In The Perjeta Market ? Some of the prominent ...

Herceptin sales dropped a third in the first nine months of the year due in part to the pandemic but mainly the impact of low-cost biosimilars, although Perjeta remains in-patent for the next few ...

Perjeta grew 17% to CHF 2.9 billion ($3.2 billion) in the first nine months of 2020, now just fractionally behind Herceptin which declined 31% to CHF 3.1 billion in the same period as biosimilars ...

And these are the list of trastuzumab based biosimilars. There are five of them. And there's also a subq version of a combination of trastuzumab and pertuzumab, which is manufactured by Genentech.